TEVA
Income statement / Annual
Last year (2024), Teva Pharmaceutical Industries Limited's total revenue was $16.54 B,
an increase of 4.41% from the previous year.
In 2024, Teva Pharmaceutical Industries Limited's net income was -$1.64 B.
See Teva Pharmaceutical Industries Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$16.54 B |
$15.85 B |
$14.93 B |
$15.88 B |
$16.66 B |
$16.89 B |
$18.85 B |
$22.39 B |
$21.90 B |
$19.65 B |
| Cost of Revenue |
$8.48 B
|
$8.20 B
|
$7.95 B
|
$8.28 B
|
$8.93 B
|
$9.35 B
|
$10.56 B
|
$11.56 B
|
$10.04 B
|
$8.30 B
|
| Gross Profit |
$8.06 B
|
$7.65 B
|
$6.97 B
|
$7.59 B
|
$7.73 B
|
$7.54 B
|
$8.30 B
|
$10.83 B
|
$11.86 B
|
$11.36 B
|
| Gross Profit Ratio |
0.49
|
0.48
|
0.47
|
0.48
|
0.46
|
0.45
|
0.44
|
0.48
|
0.54
|
0.58
|
| Research and Development Expenses |
$1.06 B
|
$953.00 M
|
$838.00 M
|
$1.09 B
|
$1.79 B
|
$1.01 B
|
$1.21 B
|
$1.85 B
|
$2.11 B
|
$1.53 B
|
| General & Administrative Expenses |
$1.16 B
|
$1.16 B
|
$1.18 B
|
$1.10 B
|
$1.17 B
|
$1.19 B
|
$1.30 B
|
$1.33 B
|
$1.24 B
|
$1.24 B
|
| Selling & Marketing Expenses |
$2.54 B
|
$2.34 B
|
$2.27 B
|
$2.43 B
|
$2.50 B
|
$2.61 B
|
$2.92 B
|
$3.66 B
|
$3.86 B
|
$3.48 B
|
| Selling, General & Administrative Expenses |
$3.70 B
|
$3.50 B
|
$3.45 B
|
$3.53 B
|
$3.67 B
|
$3.81 B
|
$4.21 B
|
$4.99 B
|
$5.10 B
|
$4.72 B
|
| Other Expenses |
$3.61 B
|
$2.76 B
|
$4.89 B
|
$1.26 B
|
$5.83 B
|
$3.16 B
|
$0.00
|
$0.00
|
$0.00
|
$23.00 M
|
| Operating Expenses |
$8.37 B
|
$7.21 B
|
$9.17 B
|
$5.88 B
|
$11.30 B
|
$7.98 B
|
$5.43 B
|
$6.83 B
|
$7.21 B
|
$6.24 B
|
| Cost And Expenses |
$16.85 B
|
$15.41 B
|
$17.12 B
|
$14.16 B
|
$20.23 B
|
$17.33 B
|
$15.99 B
|
$18.39 B
|
$17.25 B
|
$14.54 B
|
| Interest Income |
$0.00
|
$68.00 M
|
$0.00
|
$0.00
|
$24.00 M
|
$41.00 M
|
$0.00
|
$3.00 M
|
$0.00
|
$34.00 M
|
| Interest Expense |
$941.00 M
|
$1.03 B
|
$930.00 M
|
$891.00 M
|
$755.00 M
|
$957.00 M
|
$881.00 M
|
$895.00 M
|
$1.33 B
|
$465.00 M
|
| Depreciation & Amortization |
$1.06 B
|
$1.15 B
|
$1.31 B
|
$1.33 B
|
$1.56 B
|
$1.72 B
|
$1.84 B
|
$2.08 B
|
$1.49 B
|
$1.31 B
|
| EBITDA |
$4.43 B |
$1.56 B |
-$925.00 M |
$4.41 B |
$4.61 B |
$4.44 B |
$186.00 M |
-$15.52 B |
$2.87 B |
$6.34 B |
| EBITDA Ratio |
0.27
|
0.1
|
-0.06
|
0.28
|
0.28
|
0.26
|
0.01
|
-0.69
|
0.13
|
0.32
|
| Operating Income Ratio |
-0.02
|
0.03
|
-0.15
|
0.11
|
-0.21
|
-0.03
|
-0.09
|
-0.78
|
0.1
|
0.17
|
| Total Other Income/Expenses Net |
-$980.00 M
|
-$1.06 B
|
-$945.00 M
|
-$1.05 B
|
-$359.00 M
|
-$280.00 M
|
-$959.00 M
|
-$895.00 M
|
-$1.33 B
|
-$1.00 B
|
| Income Before Tax |
-$1.28 B
|
-$622.00 M
|
-$3.14 B
|
$667.00 M
|
-$3.93 B
|
-$723.00 M
|
-$2.60 B
|
-$18.38 B
|
$824.00 M
|
$2.35 B
|
| Income Before Tax Ratio |
-0.08
|
-0.04
|
-0.21
|
0.04
|
-0.24
|
-0.04
|
-0.14
|
-0.82
|
0.04
|
0.12
|
| Income Tax Expense |
$676.00 M
|
-$7.00 M
|
-$643.00 M
|
$211.00 M
|
$168.00 M
|
$278.00 M
|
-$195.00 M
|
-$1.93 B
|
$521.00 M
|
$634.00 M
|
| Net Income |
-$1.64 B
|
-$559.00 M
|
-$2.45 B
|
$417.00 M
|
-$3.99 B
|
-$999.00 M
|
-$2.15 B
|
-$16.27 B
|
$329.00 M
|
$1.59 B
|
| Net Income Ratio |
-0.1
|
-0.04
|
-0.16
|
0.03
|
-0.24
|
-0.06
|
-0.11
|
-0.73
|
0.02
|
0.08
|
| EPS |
-1.45 |
-0.5 |
-2.2 |
0.38 |
-3.64 |
-0.92 |
-2.11 |
-16.01 |
0.07 |
1.84 |
| EPS Diluted |
-1.45 |
-0.5 |
-2.2 |
0.38 |
-3.64 |
-0.92 |
-2.11 |
-16.01 |
0.07 |
1.82 |
| Weighted Average Shares Out |
$1.13 B
|
$1.12 B
|
$1.11 B
|
$1.10 B
|
$1.10 B
|
$1.09 B
|
$1.02 B
|
$1.02 B
|
$955.00 M
|
$855.00 M
|
| Weighted Average Shares Out Diluted |
$1.13 B
|
$1.12 B
|
$1.11 B
|
$1.11 B
|
$1.10 B
|
$1.09 B
|
$1.02 B
|
$1.02 B
|
$961.00 M
|
$864.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
